Literature DB >> 17081619

MHC expression and chemokine production in the murine vagina following intra-vaginal administration of ligands to toll-like receptors 3, 7 and 9.

Merja Nurkkala1, Inger Nordström1, Esbjörn Telemo1, Kristina Eriksson2.   

Abstract

The expression of MHC class I, MHC class II and the chemokines IP-10, MIP-1alpha, RANTES, fractalkine and I-TAC has been analyzed after intra-vaginal treatment with three synthetic toll-like receptors (TLR) agonists-double-stranded RNA (poly I:C), imiquimod and CpG-rich oligonucleotides (CpG-ODN). These compounds act mainly through TLR3, TLR7 and TLR9, respectively. CpG-ODN induced an accumulation of leucocytes in the vagina, and a strong up-regulation of MHC class I expression on both leucocytes and epithelial cells. Imiquimod and poly I:C induced a weak MHC class I up-regulation in the epithelium but not in the lamina propria. Neither treatment had any profound effect on expression of MHC class II on epithelial cells but poly I:C and to a lesser extent CpG-ODN, up-regulated MHC class II staining intensity which, in the case of CpG-ODN, treatment, was associated with a strong accumulation of CD11c-positive dendritic cells. All three treatments induced an early (8h) but transient IP-10 response. Imiquimod and CpG-ODN, but not poly I:C induced an early MIP-1alpha response which remained for at least 7 days in CpG-ODN-treated animals but not in imiquimod-treated mice. Poly I:C and CpG-ODN, but not imiquimod, induced significant levels of RANTES at different time-points post-treatment. None of the treatments induced any significant changes in the levels of fractalkine, I-TAC or IFN-alpha. These studies have implications for the manipulation of the genital immune response and also improving the outcome of vaginal immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17081619     DOI: 10.1016/j.jri.2006.09.001

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  6 in total

1.  Activation of Toll-like receptor 7 signaling in labial salivary glands of primary Sjögren's syndrome patients.

Authors:  T Shimizu; H Nakamura; A Takatani; M Umeda; Y Horai; S Kurushima; T Michitsuji; Y Nakashima; A Kawakami
Journal:  Clin Exp Immunol       Date:  2018-11-28       Impact factor: 4.330

2.  Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.

Authors:  Max O Meneveau; Gina R Petroni; Elise P Salerno; Kevin T Lynch; Mark Smolkin; Elizabeth Woodson; Kimberly A Chianese-Bullock; Walter C Olson; Donna Deacon; James W Patterson; William W Grosh; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

3.  Uterine epithelial cells specifically induce interferon-stimulated genes in response to polyinosinic-polycytidylic acid independently of estradiol.

Authors:  Mickey V Patel; Mimi Ghosh; John V Fahey; Charles R Wira
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

4.  Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens allows enhanced viral replication.

Authors:  Shahzada Khan; Erik M Woodruff; Martin Trapecar; Krystal A Fontaine; Ashley Ezaki; Timothy C Borbet; Melanie Ott; Shomyseh Sanjabi
Journal:  J Exp Med       Date:  2016-11-16       Impact factor: 14.307

5.  Effect of Autolyzed Yarrowia lipolytica on the Growth Performance, Antioxidant Capacity, Intestinal Histology, Microbiota, and Transcriptome Profile of Juvenile Largemouth Bass (Micropterus salmoides).

Authors:  Hui Fei; Yan Cheng; Huimin Zhang; Xiang Yu; Shunfa Yi; Mengmeng Huang; Shun Yang
Journal:  Int J Mol Sci       Date:  2022-09-15       Impact factor: 6.208

6.  Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.

Authors:  S Domingos-Pereira; L Decrausaz; L Derré; M Bobst; P Romero; J T Schiller; P Jichlinski; D Nardelli-Haefliger
Journal:  Mucosal Immunol       Date:  2012-09-12       Impact factor: 7.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.